Table 2.

Analysis of the primary efficacy endpoint, duration of severe neutropenia in cycle 1

Duration of severe neutropenia (days)	Lipegfilgrastim	Pegfilgrastim
Per-protocol population
n	41	44
Mean (SD)	0.8 (0.92)	0.9 (1.11)
Adjusted mean (95% CI)	0.7 (0.34, 1.11)	1.0 (0.60, 1.36)
Adjusted mean difference between groups (95% CI)	− 0.3 (− 0.70, 0.19)
Intent-to-treat population*
n	46	50
Mean (SD)	0.8 (0.96)	0.9 (1.08)
Adjusted mean (95% CI)	0.9 (0.29, 1.48)	1.0 (0.44, 1.59)
Adjusted mean difference between groups (95% CI)	− 0.1 (− 0.56, 0.30)

CI confidence interval, SD standard deviation

*Patients from the intent-to-treat population with evaluable values for duration of severe neutropenia